As part of this initiative, a single database was created based on insulin clinical trial data provided by several pharmaceutical industry partners from people with type 1 or type 2 diabetes in whom hypoglycaemia events occurred for the duration of the trials. The gene discussed is INS; the disease is type 2 diabetes mellitus.